At the core of the problem is the fact that India does not have a well thought-out regulatory law for biosimilars. It is crucial that the government gives this issue urgent attention because in a country like India, where much of healthcare costs are met out of pocket, the cost of medicine has a direct impact on the accessibility of medicine